Cart.com, a Houston-founded unicorn ecommerce company, has closed its latest round of funding. Photo via cart.com

Cart.com, which moved its headquarters from Houston to Austin in December but still maintains a local presence, just landed $240 million in equity and debt funding.

Legacy Knight Capital Partners, the equity investment arm of the Legacy Knight Multifamily Office, led the equity round, with participation from Citi Ventures, Visa, and other Fortune 100 companies. J.P. Morgan and TriplePoint Capital provided the debt financing. Since being founded in 2020, Cart.com has secured $380 million in funding.

“What [CEO Omair Tariq] and the team at Cart.com have accomplished in the last 14 months is nothing short of remarkable. They have proven they have the ability to rapidly execute on their vision of building the first fully end-to-end e-commerce platform at massive scale,” David Sawyer, chief operating officer and managing partner of Legacy Knight, says in a news release.

Legacy Knight has offices in Houston and Dallas. On its website, Legacy Knight Capital Partners says it makes direct investments of $10 million to $50 million in growth-stage companies and real estate projects.

“With this new funding,” Tariq says, “we’re poised to continue our strategy of acquiring top providers from across the e-commerce value chain, while staying hyper-focused on meeting the evolving needs of the brands we serve.”

Cart.com recently acquired Dallas-based FB Flurry, a provider of technology for fulfillment and customer care, and SellerActive, a Tigard, Oregon-based provider of multichannel e-commerce software.

Omair Tariq, CEO of Cart.com Omair Tariq's Cart.com raised a big round last week. Photo via Cart.com

“The Cart.com team is building a platform that can help sellers of all sizes grow faster as the future of commerce becomes increasingly digital,” says Rubail Birwadker, senior vice president of global digital partnerships at Visa.

Cart.com supplies a variety of software and services for more than 2,000 online merchants.

Last year, the startup decided to relocate its headquarters to Austin, citing the city’s rise as an alternative to Silicon Valley and as “the country’s most exciting and fertile space for high-tech innovation.”

Furthermore, Cart.com said the relocation would help the startup by being in the same business ecosystem as Austin-based companies such as Whole Foods, YETI, Kendra Scott, Tito’s Handmade Vodka, Bumble, and Tecovas.

Cart.com’s move coincided with the startup being named Startup of the Year by Capital Factory, an Austin-based startup accelerator that has offices in Houston, Dallas, and San Antonio. Capital Factory is an investor in Cart.com.

Cart.com employs more than 850 people.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Pioneering Houston biotech startup expands to Brazil for next phase

On the Move

Houston biotech company Cemvita has expanded into Brazil. The company officially established a new subsidiary in the country under the same name.

According to an announcement made earlier this month, the expansion aims to capitalize on Brazil’s progressive regulatory framework, including Brazil’s Fuel of the Future Law, which was enacted in 2024. The company said the expansion also aims to coincide with the 2025 COP30, the UN’s climate change conference, which will be hosted in Brazil in November.

Cemvita utilizes synthetic biology to transform carbon emissions into valuable bio-based chemicals.

“For decades Brazil has pioneered the bioeconomy, and now the time has come to create the future of the circular bioeconomy,” Moji Karimi, CEO of Cemvita, said in a news release. “Our vision is to combine the innovation Cemvita is known for with Brazil’s expertise and resources to create an ecosystem where waste becomes opportunity and sustainability drives growth. By joining forces with Brazilian partners, Cemvita aims to build on Brazil’s storied history in the bioeconomy while laying the groundwork for a circular and sustainable future.”

The Fuel of the Future Law mandates an increase in the biodiesel content of diesel fuel, starting from 15 percent in March and increasing to 20 percent by 2030. It also requires the adoption of Sustainable Aviation Fuel (SAF) and for domestic flights to reduce greenhouse gas emissions by 1 percent starting in 2027, growing to 10 percent reduction by 2037.

Cemvita agreed to a 20-year contract that specified it would supply up to 50 million gallons of SAF annually to United Airlines in 2023.

"This is all made possible by our innovative technology, which transforms carbon waste into value,” Marcio Da Silva, VP of Innovation, said in a news release. “Unlike traditional methods, it requires neither a large land footprint nor clean freshwater, ensuring minimal environmental impact. At the same time, it produces high-value green chemicals—such as sustainable oils and biofuels—without competing with the critical resources needed for food production."

In 2024, Cemvita became capable of generating 500 barrels per day of sustainable oil from carbon waste at its first commercial plant. As a result, Cemvita quadrupled output at its Houston plant. The company had originally planned to reach this milestone in 2029.

---

This story originally appeared on our sister site, EnergyCapitalHTX.

Texas universities develop innovative open-source platform for cell analysis

picture this

What do labs do when faced with large amounts of imaging data? Powerful cloud computing systems have long been the answer to that question, but a new riposte comes from SPACe.

That’s the name of a new open-source image analysis platform designed by researchers at Baylor College of Medicine, Texas A&M University and the University of Houston.

SPACe, or Swift Phenotypic Analysis of Cells, was created to be used on standard computers that even small labs can access, meaning cellular analysis using images produced through cell painting has a lower barrier to entry than ever before.

“The pharmaceutical industry has been accustomed to simplifying complex data into single metrics. This platform allows us to shift away from that approach and instead capture the full diversity of cellular responses, providing richer, more informative data that can reveal new avenues for drug development,” Michael Mancini, professor of molecular and cellular biology and director of the Gulf Coast Consortium Center for Advanced Microscopy and Image Informatics co-located at Baylor College of Medicine and TAMU Institute for Bioscience and Technology.

SPACe is not only accessible because of its less substantial computational needs. Because the platform is open-source, it’s available to anyone who needs it. And it can be used by academic and pharmaceutical researchers alike.

“The platform allows for the identification of non-toxic effects of drugs, such as alterations in cell shape or effects on specific organelles, which are often overlooked by traditional assays that focus largely on cell viability,” says Fabio Stossi, currently a senior scientist with St. Jude Children’s Research Hospital, the lead author who was at Baylor during the development of SPACe.

The platform is a better means than ever of analyzing thousands of individual cells through automated imaging platforms, thereby better capturing the variability of biological processes. Through that, SPACe allows scientists an enhanced understanding of the interactions between drugs and cells, and does it on standard computers, translating to scientists performing large-scale drug screenings with greater ease.

"This tool could be a game-changer in how we understand cellular biology and discover new drugs. By capturing the full complexity of cellular responses, we are opening new doors for drug discovery that go beyond toxicity,” says Stossi.

And the fact that it’s open-source allows scientists to access SPACe for free right now. Researchers interested in using the platform can access it through Github at github.com/dlabate/SPACe. This early version could already make waves in research, but the team also plans to continually improve their product with the help of collaborations with other institutions.